Michael Parker, MD
Urology · Lewiston, MENPI 1356382964
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,870 of the $4,437 with a category attached, or 87.2%. It is spread thinly across 38 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.
Across 192 payments — averaging $23.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$739
- AstraZeneca$440
- AbbVie$383
- Johnson & Johnson$334
- Sumitomo Pharma America, Inc.$288
- Bayer$273
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,87087%
- Education$56713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 29 | $739 |
| AstraZeneca | 17 | $440 |
| AbbVie(2 entities) | 14 | $383 |
| Johnson & Johnson | 11 | $334 |
| Sumitomo Pharma America, Inc. | 16 | $288 |
| Bayer | 12 | $273 |
| Merck | 12 | $238 |
| Pfizer | 11 | $180 |
| Ferring Pharmaceuticals Inc. | 9 | $153 |
| Coloplast | 7 | $128 |
| Urogen Pharma, Inc. | 3 | $110 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Myriad Genetic Laboratories, Inc. | 4 | $80 |
| Progenics Pharmaceuticals, Inc. | 3 | $78 |
| 180 Medical, Inc. | 4 | $76 |
| Amgen | 3 | $67 |
| Rochester Medical Corporation | 3 | $63 |
| Tolmar Pharmaceuticals, Inc. | 3 | $58 |
| Olympus America Inc. | 3 | $57 |
| Myovant Sciences Inc. | 3 | $54 |
| Travere Therapeutics, Inc. | 3 | $54 |
| Dentsply IH AB | 1 | $53 |
| Innovation Technologies Inc | 1 | $46 |
| Axonics, Inc. | 2 | $46 |
| Medtronic | 1 | $45 |
| Halozyme Inc | 2 | $45 |
| Teleflex LLC | 2 | $37 |
| Blue Earth Diagnostics | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Photocure Inc | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Urovant Sciences Inc | 1 | $21 |
| Sanofi | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $17 |
| Novartis | 1 | $14 |
How this compares
$4,437 in reported general payments places this provider in the 85th percentile of 59 urology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 31 | $490,493 |
| MyrbetriqMirabegron | 65 | $47,208 |
| GemtesaVibegron | 14 | $13,765 |
| Tamsulosin Hcl | 515 | $8,823 |
| Finasteride | 493 | $5,908 |
| Trimethoprim | 56 | $5,696 |
| Potassium Citrate ErPotassium Citrate | 26 | $5,413 |
| PremarinEstrogens, Conjugated | 11 | $4,781 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 95 | $4,266 |
| Solifenacin Succinate | 33 | $2,412 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 43 | $1,873 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $1,861 |
| Tolterodine Tartrate | 13 | $1,563 |
| Oxybutynin Chloride ErOxybutynin Chloride | 100 | $1,497 |
| Dutasteride | 16 | $920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $739 | $537,70196 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $288 | $13,76514 claims |
| PfizerPremarin | $180 | $4,78111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 urology providers in Maine.
Other urology in Lewiston
- Evan DunnLewiston$9K
- Christopher HenryLewiston$6K
- Christopher FooteLewiston$4K
- Jordan KurtaLewiston$2K
- Griffith BatstoneFarmington$123K
- David SobelPortland$58K
- Marc HodroffPortland$17K
- Robert FisherRockport$9K
- Jesse SammonSouth Portland$6K
- Sanchita BoseSouth Portland$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.